

14. The method of claim 13, wherein the retinoid X receptor antagonist is selected from LG100754, AGN195393, Ro26-5405, LG101506, PA451, PA452, B1-1003, B1-1005, SR11179, UVI3003, Danthron, Rhein, β -Apo-13-carotenone, R-Etodolac, Sulindac sulfide, K-80003, K-8008, Triptolide, TRC4, NSC-640358, Fluvastatin, Pitavastatin, HX531 or a combination thereof.

15. The method of claim 9, wherein the patient also has prostate cancer.

16. The method of claim 9, wherein the method further comprises administering agents that counter the effect of androgens.

17. The method of claim 16, wherein the agents that counters the effect of androgens are sex hormone-binding globulin (SHBG) stimulators.

18. The method of claim 9, wherein the method further comprises administering an antigonadotropin.

19. The method of claim 9, wherein the method further comprises administering a mineralocorticoid or a glucocorticoid.

20. The method of claim 9, wherein the method further comprises administering an insulin sensitizing medication.

21. The method of claim 9, wherein the method further comprises administering a vaccine or immunogens against androstenedione.

22. A composition used to treat of a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the composition comprises an anti-androgen, an anti-thyroid medication, a thyroid receptor antagonist, a TGF- β inhibitor or a combination thereof.

23. The composition of claim 22, wherein the composition is formulated with a carrier or delivery vehicle optimized for delivery to the lung.

24. The composition of claim 23, wherein the carrier or delivery vehicles is selected from liposomes, non-ionic liposomes, niosomes, novasome I, erythromycin-Zn complex, microspheres, nanoparticles, solid lipid nanoparticles or nanoemulsions.

25. The composition of claim 22, wherein the composition is formulated to be administered either orally, nasally, topically, intramuscularly, intravenously or by inhalation.

26. The composition of claim 22, wherein the anti-androgen is enzalutamide or any deuterated form thereof.

27. The composition if claim 22, wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, SSKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof.

28. The composition of claim 22, wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof.

29. The composition of claim 22, wherein the TGF- β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof.

30. A composition used to treat of a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the composition comprises an anti-thyroid medication, a thyroid receptor antagonist, a TGF- β inhibitor or a combination thereof.

* * * * *